As part of our commitment to advancing patient care, the Vascular and Interventional Radiology Section at New York University Medical Center participates in multiple ongoing clinical trials to assess promising new treatments for the wide variety of conditions we treat. We are currently accruing patients for the following clinical trials. For more information or to see if you or your patient is eligible for one of these trials, please call us at 212-263-5898.
Cardiovascular Outcomes with Renal Atherosclerotic Lesions (CORAL)
This is a randomized, multicenter prospective trial of patients with atherosclerotic blockage of blood flow to the kidneys, which may be present in up to 3 million Americans. The purpose of the CORAL trial is to test the hypothesis that stenting of atherosclerotic renal artery stenosis in patients with systolic hypertension reduces the incidence of cardiovascular and renal events. More information can be obtained at www.coralclinicaltrial.org <http://www.coralclinicaltrial.org/> . To discuss a potential patient with a member of our team, please call 212-263-5898.
A Prospective, Randomized, Active-Control, Multicenter Study Assessing Overall Survival using Chemotherapy with or without Radiofrequency Ablation for Subjects with Colorectal Cancer and Incurable Metastatic Disease, Failing First-Line Chemotherapy
This is a randomized multicenter trial of patients with colorectal metastatic tumors to the liver. The purpose of the trial is to evaluate the potential benefit on survival of patients who undergo radiofrequency ablation of liver tumors and systemic chemotherapy, compared to treatment with systemic chemotherapy alone. Eligible patients are those with liver-dominant metastatic disease to the liver and no contraindications to radiofrequency ablation. To discuss a potential patient with a member of our team, please call 212-263-5898.
Functional MRI of the Liver in Patients Undergoing Transarterial Chemoembolization (TACE)
This is a feasibility study of using sophisticated MRI-based imaging techniques to evaluate treatment response following hepatic chemoembolization. Hepatic chemoembolization is a minimally invasive procedure which involves selective placement of a catheter, using a femoral artery approach, into the branches of the hepatic artery supplying one or more liver tumors. Once the catheter has been navigated into the blood vessels nourishing the tumor(s) a small volume of highly concentrated chemotherapy can be delivered directly to the tumor blood vessels, achieving localized drug levels far higher than what could be achieved using systemic chemotherapy treatment. In addition, this targeted type of treatment dramatically reduces the side effects associated with a chemotherapeutic agent. Once the chemotherapeutic agent is delivered to the lesion, tiny particles of special plastic are injected into the blood vessels to deprive the tumor(s) of oxygen and nutrients. This study evaluates the effects of chemoembolization on the tumor(s) using functional MRI, including diffusion-weighted, perfusion-weighted, blood oxygenation level-dependent (BOLD) and MR spectroscopy. The long term goals of this research are to improve the monitoring of patients following chemoembolization to allow more preciseassessment of patients who may require additional chemoembolization to control their tumor burden.